Evidence map›Paper›PMID 24848085›Full record

ArticlePloS one2014

Association between oestrogens receptor expressions in breast cancer and comorbidities: a cross-sectional, population-based study.

Laure de Decker, Mario Campone, Frederique Retornaz, Gilles Berrut, Anastasia Kabeshova, Florence Molinié, Olivier Beauchet

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Laure de DeckerDepartment of Therapeutic, EA 1156-12, Division of Geriatric Medicine, Nantes University Hospital, Nantes, France.
Mario CamponeOuest Cancer Institut, UMR-INSERM U892, Nantes, France.
Frederique RetornazDepartment of Departmental Geriatrics, Marseille, France.
Gilles BerrutDepartment of Therapeutic, EA 1156-12, Division of Geriatric Medicine, Nantes University Hospital, Nantes, France.
Anastasia KabeshovaDepartment of Neuroscience, UPRES EA 4638, UNAM, Division of Geriatric Medicine, Angers University Hospital, Angers, France.
Florence MoliniéOuest Cancer Registry, Nantes, France.
Olivier BeauchetDepartment of Neuroscience, UPRES EA 4638, UNAM, Division of Geriatric Medicine, Angers University Hospital, Angers, France.
Nantes Université · FRUniversité d'Angers · FRCancéropôle Grand Ouest · FRInstitut de Cancérologie de l'Ouest · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer with oestrogen receptor expression is common in older women. Several factors, such as age and reproductive hormone exposure, have been associated with oestrogen receptor expression in breast cancer. However, the association between comorbidities and the oestrogen receptor expression has been poorly studied. We hypothesized that there was an association between burden comorbidity and breast cancer with oestrogen receptor expression in older women.

objectiveTo determine whether oestrogen receptor expression in breast cancer was associated with burden comorbidity in community-dwelling women.

methodsA total of 1,707 women with breast cancer registered on the list of a breast cancer registry were included. The recorded data included: age, Charlson Comorbidity Index score≥1, breast cancer characteristics (coded according to the International Classification of Diseases for Oncology), and breast cancer pathological stage (the pathological-tumour-node-metastasis, Scarff Bloom Richardson, and hormonal status of oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor).

resultsBreast cancer with oestrogen receptor expression was identified in 1,378 patients (80·7%). The fully-adjusted logistic regression showed that oestrogen receptor expression was associated with Charlson Comorbidity Index score≥1 (odds ratio [OR] = 1·91,95%confidence interval [CI] = [1.01-3.61], P = 0·048), progesterone receptor expression (OR = 16·64, 95%CI = [11.62-23.81], P<0·001), human epidermal growth factor receptor (OR = 0·54, 95%CI = [0.34-0.84], P = 0·007), age (OR = 1.02, 95%CI = [1.00-1.03], P = 0.008), Scarff Bloom Richardson grade II and grade III (OR = 0·21with 95%CI = [0.10-0.44] and OR = 0·06 with 95%CI = [0.03-0.12], P<0·001).

conclusionOur findings provide new data showing an independent positive association between burden comorbidity and breast cancer with oestrogen receptor expression. This result confirms that evaluation of oestrogen receptor expression in breast cancer should not be limited to hormonal factors stratified by age.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsComorbidityCross-Sectional StudiesErbB ReceptorsEstrogen Receptor alphaFemaleHumansLogistic ModelsMiddle AgedNeoplasm MetastasisOdds RatioReceptors, ProgesteroneRegistriesErbB ReceptorsESR1 protein, humanEstrogen Receptor alphaReceptors, Progesterone

Identifiers

PMID24848085
PMCPMC4029934
OpenAlexW2094993469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.